NanoBio Corporation

Activities: Research & Development Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Research & Development

Merck & Co licenses NanoBio technology for use in vaccine development

NanoStat uses an oil-in-water nanoemulsion that can incorporate, deliver and act as an adjuvant for multiple antigen types
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Helping the delivery of biotech-based therapies

Modern biotech-derived medicines require new methods to aid targeted delivery. Dr Sarah Houlton, looks at some of the novel nano-based technologies that are getting results
Research & Development

NanoBio receives US$10m from NIH to develop pandemic flu vaccine

Funding will be used to research nanoemulsion-adjuvanted HIV vaccine
Drug Delivery

HPA awarded £4m contract by US government to develop anthrax vaccine

Will be delivered by an intra-nasal spray device instead of an injection
Subscribe now